

Short term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy: The EuroSIDA risk-score

A Mocroft¹, B Ledergerber², K Zilmer³, O Kirk⁴, B Hirschel⁵, JP Viard⁶, P Reiss⁷, P Francioli⁸, A Lazzarin⁹, L Machala¹⁰, AN Phillips¹, JD Lundgren⁴ for the EuroSIDA study group and the Swiss HIV Cohort Study*

¹Royal Free and University College Medical School, UK; ²University Hospital Zurich, Switzerland; ³West-Tallinn Central Hospital, Estonia; ⁴Hvidovre Hospital, Denmark; ⁵Geneva University Hospital, Switzerland; ⁶Hôpital Necker-Enfants Malades, France; ⁷Academisch Medisch Centrum bij de Universiteit van Amsterdam, The Netherlands; ⁸University Hospital Lausanne, Switzerland; ⁹Ospedale San Raffaele, Italy; ¹⁰Faculty Hospital Bulovka, *members of the study groups listed below.

BACKGROUND

- Predicting HIV clinical progression using prognostic scores normally concentrates on predicting long-term clinical progression based on information known at starting cART
- It could be clinically more relevant to accurately assess the risk of clinical progression in the next 3 or 6 months at any time after starting cART, based on the laboratory results currently known

OBJECTIVES

- To develop a EuroSIDA risk-score to predict the short term risk of clinical progression (new AIDS or death)
- To validate this score in the Swiss HIV Cohort Study (SHCS)

PATIENTS (N=3338)

- Patients starting cART (defined as exactly 2 nucs, plus either a single PI, a ritonavir-boosted PI, NNRTI, or abacavir) with CD4/VL measured before starting cART
- Haemoglobin and BMI measured during follow-up

METHODS

- Poisson regression, all variables included as time-updated

THE EUROSIDA RISK SCORE

- 616 new AIDS/deaths during 18,203 PYFU
- CD4, rate of change of CD4, VL, BMI, level of anaemia, prior ARV treatment, and current ARV treatment were related to clinical progression
- EuroSIDA risk-score shown in Figure 1
- Example shown in Figure 2

A single unit increase in the current EuroSIDA risk-score was associated with a 2.70 times higher incidence of clinical progression (95% CI 2.57 – 2.85, p<0.0001)

The EuroSIDA risk-score was divided into 4 groups; <1.5, 1.5-2.99, 3-4.49 and ≥4.5. Figure 3 illustrates the chance of clinical progression within the next 3, 6 or 12 months after a clinic visit, within these 4 strata.

VALIDATION IN THE SHCS

- 4,700 patients from the SHCS satisfied the inclusion criteria and were included as the validation cohort

Figure 4 illustrates the incidence rates of new AIDS/death after stratification by current EuroSIDA risk-score in both EuroSIDA and the SHCS

In the SHCS patients, a single unit increase in the current EuroSIDA risk-score was associated with a 2.84 times higher incidence rate of clinical progression (95% CI 2.71–2.99, p<0.0001)

CONCLUSIONS

- Current CD4, viral load, level of anaemia, BMI, and rate of CD4 change were highly prognostic for new AIDS/death
- A risk-score was derived and validated on SHCS patients with good agreement
- A patient with a EuroSIDA risk-score of less than 1.5 had a 1 in 629 chance of disease progression within the next 3 months, compared to a chance of 1 in 12 for a patient whose EuroSIDA risk-score was over 4.5
- The EuroSIDA risk-score will be made publicly available on a website where relevant details can be entered and the score calculated without the need for clinicians to calculate the CD4 slope
- The EuroSIDA risk-score is highly clinically relevant for patient management, or for use as a surrogate endpoint in clinical trial design.

ACKNOWLEDGEMENTS

The EuroSIDA Study Group (national coordinators in parenthesis)

Argentina: (M Lasso), A Duran, Hospital JM Ramos Mejia, Buenos Aires. **Austria:** (N Vetter) Pulmologisches Zentrum der Stadt Wien, Vienna. **Belarus:** (I Karпов), A Vassilenko, Belarus State Medical University, Minsk. **Belgium:** (N Clumeck) S De Wit, B Poll, Saint-Pierre Hospital, Brussels; R Colebunders, Institute of Tropical Medicine, Antwerp. **Czech Republic:** (L Machala) H Rozsypal, Faculty Hospital Bulovka, Prague; D Sedláček, Charles University Hospital, Pilsen. **Denmark:** (J Nielsen) J Lundgren, T Benfield, O Kirk, Hvidovre Hospital, Copenhagen; J Gerstoft, T Katzenstein, A-B E Hansen, P Skinhaj, Rigshospitalet, Copenhagen; C Pedersen, Odense University Hospital, Odense. **Estonia:** (K Zilmer) West-Tallinn Central Hospital, Tallinn. **France:** (C Katlama) Hôpital de la Pitié-Salpêtrière, Paris; J P Viard, Hôpital Necker-Enfants Malades, Paris; P M Girard, Hôpital Saint-Antoine, Paris; T Saint-Marc, Hôpital Edouard Belin, Lyon; P Vanhems, University Claude Bernard, Lyon; C Pradier, Hôpital de l'Archet, Nice; F Dabis, Unité INSERM, Bordeaux. **Germany:** (M Dietrich), C Manege, Bernhard-Nocht-Institut für Tropische Medizin, Hamburg; J van Lunzen, HJ Stelibrink, Eppendorf Medizinische Klinik, Hamburg; S Staszewski, M Bickel, JW Goethe University Hospital, Frankfurt; F D Goebel, Medizinische Poliklinik, Munich; G Falkenheuer, Universität Köln, Cologne; J Rockstroh, Universitätsklinik Bonn; R Schmidt, Medizinische Hochschule Hannover. **Greece:** (I Kosmidis) P Gargalianos, G Xylomenos, J Perdios, Athens General Hospital, Athens; G Panos, A Filandras, E Karabatsaki, 1st IKA Hospital, Athens. **Hungary:** (D Banhegyi) Szent László Hospital, Budapest. **Ireland:** (F Mulcahy) St. James's Hospital, Dublin. **Israel:** (I Yust) D Turner, M Burke, Ichilov Hospital, Tel Aviv; S Pollack, G Hassoun, Rambam Medical Center, Haifa; Z Silberger, Kaplan Hospital, Rehovot; S Maayan, Hadassah University Hospital, Jerusalem. **Italy:** (A Chiari) Istituto Superiore di Sanità, Rome; R Esposito, I Mattei, Università Modena, Modena; C Anici, Ospedale Riuniti, Bergamo; R Pirovano, Ospedale Generale Regionale, Bolzano; F Mazzotta, A Gabutti, Ospedale S Maria Annunziata, Firenze; Vullo, M Lichtner, University of Roma La Sapienza, Rome; A Chirriani, E Montesarchio, Presidio Ospedaliero AD, Colongo, Monaldi Hospital, Napoli; Antonucci, F Iacomi, Narciso, Zaccarelli, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome; A Lazzarin, R Finazzi, Ospedale San Raffaele, Milan; A D'Arminio Monforte, Osp. L. Sacco, Milan. **Latvia:** (L Viksna) Infectology Centre of Latvia, Riga. **Lithuania:** (S Chaplinskas) Lithuanian AIDS Centre, Vilnius. **Luxembourg:** (R Hemmer), T Staub, Centre Hospitalier, Luxembourg. **Netherlands:** (P Reiss) Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam. **Norway:** (I Bruun) A Maeland, V Ormaasen, Ullevål Hospital, Oslo. **Poland:** (B Knysz) J Gasiórowski, Medical University, Wrocław; A Horban, Centrum Diagnostyki i Terapii AIDS, Warszawa; D Prokopowicz, A Wiercinska-Drapalo, Medical University, Białystok; A Boron-Kaczmarek, M Pynka, Medical University, Szczecin; M Beniowski, E Malarska, Ośrodek Diagnostyki i Terapii AIDS, Chorzów; H Trocha, Medical University, Gdańsk. **Portugal:** (P Antunes) E Valadas, Hospital Santa Maria, Lisbon; R Mansinho, Hospital de Egas Moniz, Lisbon; F Malta, Hospital Curry Cabral, Lisbon. **Romania:** (D Duiculescu) Spitalul de Boli Infectioase si Tropicale, Dr. Victor Babes, Bucuresti; A Stinescu-Cercet, Institute of Infectious Diseases, Bucuresti. **Russia:** (S Vinogradov), St Petersburg AIDS Centre, A Rakhmanova, Medical Academy Borisk Hospital, St Petersburg. **Serbia & Montenegro:** (D Jentovic), The Institute for Infectious and Tropical Diseases, Belgrade. **Slovakia:** (M Mokros) D Staneková, Déer Hospital, Bratislava. **Spain:** (J González-Lahoz) M Sánchez-Conde, T García-Benayas, L Martín-Carbonero, V Soriano, Hospital Carlos III, Madrid; B Clotet, A Jou, J Conejero, C Turat, Hospital Germans Trias i Pujol, Badalona; JM Gatell, JM Miró, Hospital Clinic i Provincial, Barcelona; P Domingo, M Gutiérrez, G Mateo, MA Sampedro, Hospital Sant Pau, Barcelona. **Sweden:** (A Blaxhult) Karolinska University Hospital, Solna; A Karlsson, Karolinska University Hospital, Stockholm; P Pehrson, Karolinska University Hospital, Huddinge. **Switzerland:** (B Ledergerber) R Weber, University Hospital, Zürich; P Francioli, A Telenti, Centre Hospitalier Vaudois, Lausanne; B Hirschel, V Soriano-Duand, Hôpital Cantonal Universitaire de Genève, Genève; H Furrer, Inselspital Bern. **Ukraine:** (E Kravchenko) H Chentsova, Kyiv Centre for AIDS, Kyiv. **United Kingdom:** (S Barton) St. Stephen's Clinic, Chelsea and Westminster Hospital, London; J Johnson, D Mercey, Royal Free and University College London Medical School, London (University College Campus); A Phillips, MA Johnson, R Phillips, MA Johnson, Royal Free and University College London (Royal Free Campus); M Murphy, Medical College of Saint Bartholomew's Hospital, London; J Weber, G Scullard, Imperial College School of Medicine at St. Mary's, London; M Fisher, Royal Sussex County Hospital, Brighton; R Phillips, Western General Hospital, Edinburgh. **Virology group:** S Clotet (Central Coordinators) plus ad hoc virologists from participating sites in the EuroSIDA Study. **Steering Committee:** F Antunes, B Clotet, D Duiculescu, J Gatell, B Gazzard, A Horban, Karlsson, C Katlama, B Ledergerber (Chair), A D'Arminio Monforte, AN Phillips, A Rakhmanova, P Reiss (Vice-Chair), J Rockstroh. **Coordinating Centre Staff:** JD Lundgren (project leader), I Gjener, O Kirk, A Mocroft, N Friis-Møller, A Cozzi-Lepri, W Bannister, M Ellefson, A Borch, D Podlekareva, C Holkmann Olsen, J Kjaer

The Swiss HIV Cohort Study

M. Battegay, E Bernasconi, J Böni, H Bucher, Ph. Burgisser, S. Cattacin, M. Cavassini, R. Dubs, M. Egger, L. Elzi, P. Erb, M. Fischer, M. Flepp, A. Fontana, P. Francioli (President), H. Furrer (Chairman of the Clinical and Laboratory Committee), M. Gorgievski, H. Günthard, B. Hirschel, L. Hösli, Ch. Kahler, L. Kaiser, U. Karrer, O. Keiser, C. Kind, Th. Klimkait, B. Ledergerber, B. Martinez, N. Müller, M. Opravi, F. Paccaud, G. Pantaleo, L. Perrin, L.-C. Piffaretti, M. Rickenbach (Head of Data Center), C. Rudin (Chairman of the Mother & Child Substudy), P. Schmid, D. Schultze, J. Schüpbach, R. Speck, P. Taffe, P. Tarr, A. Telenti, A. Tsiolis, P. Vernazza (Chairman of the Scientific Board), R. Weber, S. Yerly.



Swiss
HIV
Cohort
Study

Figure 1

The EuroSIDA risk-score

	If current (latest)		If current (latest)
+0	CD4 > 350/mm ³	+0.54	BMI ≤18
+0.61	CD4 201-350/mm ³	+0	BMI 18.1-25
+1.55	CD4 51-200/mm ³	-0.29	BMI > 25
+2.53	CD4 ≤ 50/mm ³	+0.48	CD4 slope < -25/mm ³ per 3 months
+0	Viral load < 500 copies/ml	+0	CD4 slope -25 to +25/mm ³ per 3 months
+0.15	Viral load ≥ 500 copies/ml	+0.20	CD4 slope ≥ 25/mm ³ per 3 months
+0	No anaemia	+0	If ARV experienced prior to cART
+0.78	Mild anaemia	-0.34	If ARV naïve prior to cART
+2.05	Severe anaemia	+0	Taking any antiretrovirals
+0.024	x age (In years)	+1.24	Off all antiretrovirals

Figure 2

Example of EuroSIDA risk-score

- 30 year old patient
- Started cART from ARV naïve
- Current CD4 count 400/mm³, viral load 50 copies/ml
- Currently BMI of 22 and mild anaemia
- CD4 slope increased by 15/mm³ over the past 3 months
- Currently taking cART

EuroSIDA risk-score = 1.16

0 (CD4 component) + 0 (viral load component) + 0.78 (mild anaemia) + 0 (BMI component) + 0.024*30 (age) + 0 (CD4 slope component) + 0 (on cART) + 0 (ARV experienced)

Figure 3

Clinical progression according to EuroSIDA risk-score

	Chance of New AIDS/Death	95% Confidence Interval
Within 3 months		
EuroSIDA <1.5	1 In 607	1 In 477 to 1 In 834
Risk-score 1.5 – 2.99	1 In 185	1 In 161 to 1 In 218
3.0 – 4.49	1 In 42	1 In 36 to 1 In 49
≥ 4.5	1 In 13	1 In 12 to 1 In 15
Within 6 months		
EuroSIDA <1.5	1 In 304	1 In 239 to 1 In 417
Risk-score 1.5 – 2.99	1 In 93	1 In 81 to 1 In 109
3.0 – 4.49	1 In 21	1 In 18 to 1 In 25
≥ 4.5	1 In 7	1 In 6 to 1 In 8
Within 12 months		
EuroSIDA <1.5	1 In 152	1 In 120 to 1 In 209
Risk-score 1.5 – 2.99	1 In 47	1 In 41 to 1 In 55
3.0 – 4.49	1 In 11	1 In 9 to 1 In 13
≥ 4.5	1 In 4	1 In 3 to 1 In 5

Figure 4

Incidence of new AIDS/death stratified by current EuroSIDA risk-score

